

Cardiogenesis Corp /CA  
Form 8-K  
November 05, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 3, 2010**

**CARDIOGENESIS CORPORATION**

*(Exact name of registrant as specified in its charter)*

**California**  
*(State or other  
jurisdiction of  
incorporation)*

**000-28288**  
*(Commission File Number)*

**77-0223740**  
*(IRS Employer  
Identification No.)*

**11 Musick  
Irvine, CA 92618**

*(Address of principal executive offices, including zip code)*

Registrant's telephone number, including area code: **(949) 420-1800**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operation and Financial Condition**

On November 3, 2010, Cardiogenesis Corporation (the Company ) issued a press release announcing its financial results for the quarter ended September 30, 2010. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Also on November 3, 2010, the Company held a conference call with analysts and investors to report its financial results for the quarter ended September 30, 2010. The transcript of the conference call is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Form 8-K, including Exhibits 99.1 and 99.2, are furnished pursuant to Item 2.02 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release of Cardiogenesis Corporation dated November 3, 2010.
99.2	Conference Call Transcript dated November 3, 2010.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIOGENESIS CORPORATION  
(Registrant)

Date: November 5, 2010

By: /s/ William Abbott  
William Abbott, Chief Financial Officer  
and Secretary

---

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release of Cardiogenesis Corporation dated November 3, 2010.
99.2	Conference Call Transcript dated November 3, 2010.